IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
— ICVB-1042 is an oncolytic adenovirus for the treatment of advanced solid tumors —— Initial safety data expected in 2H 2023, followed by proof-of-concept data in 2024 — SAN DIEGO, CA., July 11, 2023 – IconOVir Bio, Inc. (IconOVir), a clinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the […]
IconOVir Bio to Present at Jefferies Healthcare Conference
SAN DIEGO, CA., May 31, 2023 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare […]
IconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference
SAN DIEGO, CA., March 7, 2023 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Oppenheimer 33rd […]
IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022
— ICVB-1042 demonstrates selective replication, broad tropism and anti-tumor activity across multiple in vitro and in vivo models — — Proprietary Ad5/Ad34 mutation improves viral entry into target tumor cells, enhancing tropism — — On track to initiate Phase 1 trial in solid tumors in 1H 2023 — SAN DIEGO, CA., November 10, 2022 – […]
IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer
SAN DIEGO, CA., Oct. 10, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of Julia (Julie) Maltzman, M.D., as its Chief Medical Officer. Dr. Maltzman brings over three decades of experience as […]
IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022
SAN DIEGO, CA., Oct. 5, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that it will present preclinical data on ICVB-1042 in three poster presentations at the upcoming Annual Meeting of the Society for […]
IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium
SAN DIEGO, CA., Sept. 14, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Biotechnology […]
IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors
SAN DIEGO, CA., June 23, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced the appointment of William G. Kaelin Jr., M.D., to its Board of Directors. Dr. Kaelin will continue to serve as a member […]
IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer
SAN DIEGO, CA., June 6, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of John Huynh, Ph.D., as the Company’s first Chief Technology Officer. Dr. Huynh brings nearly two decades of experience […]
IconOVir Bio to Present at Jefferies Healthcare Conference
SAN DIEGO, CA., June 3, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare […]